ACLARION, INC. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ACLARION, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2024-09-30 was $0.00.
- ACLARION, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2024-06-30 was $0.00.
- ACLARION, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2024-03-31 was $0.00.
- ACLARION, INC. stock issued during period, value, restricted stock award, gross for fiscal 2024 was $0.00.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-18 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |